Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira
March 06, 2017 at 04:09 AM EST
Sandoz, a Novartis (NYSE: NVS) division, and the pioneer and global leader in biosimilars, today presented data for its proposed ...
